Can immunotherapy open the door to liver transplants for more cancer patients?

NCT ID NCT07489976

First seen Apr 06, 2026 · Last updated Jun 15, 2026 · Updated 14 times

Summary

This study tests whether combining immunotherapy with a liver-directed tumor procedure can safely shrink liver cancer (hepatocellular carcinoma) enough to make patients eligible for a liver transplant. About 41 adults with advanced liver cancer will receive this combination therapy. The main goal is to see how many patients' tumors shrink to within transplant criteria within 12 months, while closely monitoring side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cedars Sinai

    RECRUITING

    Los Angeles, California, 90048, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.